Population Pharmacokinetics and Exposure-Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma.
Divya SamineniWeize HuangLeonid GibianskyHao DingRong ZhangChunze LiArijit SinhaRicha RajwanshiKathryn HumphreyAlexandra BazeosAhmed Hamed SalemDale MilesPublished in: Advances in therapy (2021)
ClinicalTrials.gov Identifier NCT02055820.